Skip to content
HowShorted

FILANA THERAPEUTICS, INC. short interest in 2023

In 2023, FILANA THERAPEUTICS, INC.'s disclosed short interest ran from 25.76% of shares outstanding on 13 Jan 2023 to 32.93% on 29 Dec 2023, a change of +7.17 percentage points. The year's high was 38.11% on 31 Oct 2023 and its low 22.48% on 15 Jun 2023, averaging 28.71% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 23.60 days on 28 Apr 2023. Full history: FILANA THERAPEUTICS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for FILANA THERAPEUTICS, INC. in 2023

2023 in figures

Start of year
25.76% (13 Jan 2023)
End of year
32.93% (29 Dec 2023)
Change
+7.17 pp
High
38.11% (31 Oct 2023)
Low
22.48% (15 Jun 2023)
Average
28.71%
Highest days to cover
23.60 (28 Apr 2023)
SEC filings marked
8

Every report in 2023

FILANA THERAPEUTICS, INC. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 202325.76%8.13
31 Jan 202324.59%3.83
15 Feb 202326.46%8.10
28 Feb 202326.38%16.0910-K filed, results (8-K)
15 Mar 202325.05%12.47
31 Mar 202327.56%15.61
14 Apr 202326.48%21.51
28 Apr 202326.31%23.60
15 May 202324.34%10.2010-Q filed, results (8-K)
31 May 202325.88%15.87
15 Jun 202322.48%15.54
30 Jun 202324.30%19.58
14 Jul 202326.83%6.89
31 Jul 202327.37%15.94
15 Aug 202329.21%13.6110-Q filed, results (8-K)
31 Aug 202331.80%12.77
15 Sep 202332.65%17.44
29 Sep 202333.86%21.08
13 Oct 202333.40%8.22
31 Oct 202338.11%7.59
15 Nov 202334.51%11.5310-Q filed, results (8-K)
30 Nov 202332.52%21.35
15 Dec 202330.25%7.42
29 Dec 202332.93%9.07

See also: FILANA THERAPEUTICS, INC.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.